Gilead To Become Victim Of Own Success In Japan?
This article was originally published in PharmAsia News
Gilead Sciences is on a roll both globally and in Japan, where two of its key drugs for hepatitis C have been launched this year and the California-based company is planning to roll out other pipeline products, including in oncology. But the rapid sales growth for its HCV products is raising the specter of possible price cuts.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.